Home' Australian Pharmacist : Australian Pharmacist October 2016 Contents Australian Pharmacist October 2016 I ©Pharmaceutical Society of Australia Ltd.
ZO-RUB® OA and HP: Targeted action to relieve pain
Two new topical capsaicin cream
treatments provide targeted pain relief
for patients -- ZO-RUB® OA (capsaicin
0.025% w/w, 45g) for osteoarthritis pain
and ZO-RUB® HP (capsaicin 0.075% w/w,
45g) for the relief of neuropathic pain.
Zo-Rub® OA is a topical analgesic
cream that works directly at the source
to relieve the pain of Osteoarthritis
in both large and small joints. Zo-
Rub® OA is a specific treatment for
chronic osteoarthritis pain unlike other
treatments such as topical NSAID's,
and is clinically proven to reduce
osteoarthritis pain in monotherapy1 and
in combination with Paracetamol or oral
Zo-Rub® HP cream is a well-tolerated
treatment for the management of
painful diabetic neuropathy and post
herpetic neuralgia, helping to provide
effective pain relief and an improved
quality of life.3,4,5
For further information about ZO-RUB®
OA and HP contact AFT Pharmaceuticals
on 1800 AFTPHARM (1800 2387 4276).
Southernature natural supplement range
Southernature is now available to
pharmacies nationally and, according to
the company, comes with a commitment
to provide Australian pharmacy with
the most effective and highest quality
natural supplements available locally,.
The Southernature natural supplement
range boasts a number of certifications
from independent bodies including
International Fish Oil StandardsTM
(IFOS), Good Manufacturing Practices
(GMP), Friend of the Sea and the
Global Organisation for EPA and DHA
Omega-3s. Within its broader range,
Southernature also offers 100% Vegan
Friendly supplements which use plant-
based ingredients and capsules.
Southernature Chief Executive Officer
Vincent Tai, said the company has big
ambitions in the pharmacy channel.
'While Southernature is a new player
to the Australian market, we have a
long-term strategy in place to expand
our footprint in pharmacies nationally.
We are committed to supporting the
pharmacy channel across our product
range via education and training,
professional services support, consumer
marketing support, as well as discounts
to award business loyalty,' Mr Tai said.
'As a company we do not compromise
on quality. Southernature invests heavily
in research and development to ensure
all products are derived from the very
best of ingredients and formulated
to the highest grade possible. The
certifications and endorsements our
products hold, talk for themselves.
For example, Southernature products
that contain Omega-3 only use
certified 5-star fish oil, as rated by the
International Fish Oil Standards (IFOS).'
The product range includes Women's
Health, Men's Health, Kid's Health,
General Health and Functional Health.
For further information visit: www.
Samsung Bioepis has announced that
Brenzys, a biosimilar referencing Enbrel
(etanercept), also known as SB4, has
received regulatory approval in Canada
for the treatment of rheumatoid arthritis
and ankylosing spondylitis. Brenzys will
be commercialized in Canada by Merck
'As evidenced in other markets, we
believe Brenzys will help drive down
healthcare costs and increase patient
access to one of the most widely used
autoimmune treatment options in
Canada,' Christopher Hansung Ko,
President & CEO of Samsung Bioepis
said. Before receiving approval
in Canada, Samsung Bioepis' SB4
etanercept biosimilar received
regulatory approvals from Korea's
Ministry of Food and Drug Safety
(MFDS) as Brenzys in September 2015,
the European Commission (EC) as
Benepali in January 2016 and Australia's
Therapeutic Goods Administration as
Brenzys in July 2016.
1. Altman RD et al. Capsaicin Cream 0.025% as Monotherapy
for Osteoarthritis: A Double-Blind Study. Seminars in
Arthritis and Rheumatism 1994; 23 (6): 25-33.
2. Deal CH et al. Treatment of arthritis with topical capsaicin: a
double-blind trial. Clin Ther 1991: 13 (3): 383-395.
3. Daily GE for the Capsaicin Study Group. Effect of capsaicin
on daily activities of patients with painful diabetic
neuropathy. Diabetes Care 1992; 15 (2): 159--1654.
4. Watson PC et al. A randomised vehicle-controlled trial
of topical capsaicin in the treatment of post herpetic
neuralgia. Clin Ther 1993: 15 (3): 510-526.
5. Sheffler NM et al. Treatment of painful diabetic neuropathy
with capsaicin 0.075%. J Am Pod Med Assoc 1991; 81 (6):
Links Archive Australian Pharmacist September 2016 Australian Pharmacist November 2016 Navigation Previous Page Next Page